These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 32043089)
21. A foundation for reference models for drug combinations with an application to Loewe's reference model. De Mulder W; Kuiper M BMC Bioinformatics; 2020 Oct; 21(1):460. PubMed ID: 33059599 [TBL] [Abstract][Full Text] [Related]
22. Statistical detection of synergy: New methods and a comparative study. Thas O; Tourny A; Verbist B; Hawinkel S; Nazarov M; Mutambanengwe K; Bijnens L Pharm Stat; 2022 Mar; 21(2):345-360. PubMed ID: 34608741 [TBL] [Abstract][Full Text] [Related]
29. A New Bliss Independence Model to Analyze Drug Combination Data. Zhao W; Sachsenmeier K; Zhang L; Sult E; Hollingsworth RE; Yang H J Biomol Screen; 2014 Jun; 19(5):817-21. PubMed ID: 24492921 [TBL] [Abstract][Full Text] [Related]
30. Non-parametric synergy modeling of chemical compounds with Gaussian processes. Shapovalova Y; Heskes T; Dijkstra T BMC Bioinformatics; 2022 Jan; 23(1):14. PubMed ID: 34991440 [TBL] [Abstract][Full Text] [Related]
31. A generalized response surface model with varying relative potency for assessing drug interaction. Kong M; Lee JJ Biometrics; 2006 Dec; 62(4):986-95. PubMed ID: 17156272 [TBL] [Abstract][Full Text] [Related]
32. Analysis of drug combinations: current methodological landscape. Foucquier J; Guedj M Pharmacol Res Perspect; 2015 Jun; 3(3):e00149. PubMed ID: 26171228 [TBL] [Abstract][Full Text] [Related]
33. Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition. Lederer S; Dijkstra TMH; Heskes T Front Pharmacol; 2018; 9():31. PubMed ID: 29467650 [TBL] [Abstract][Full Text] [Related]
34. Revisiting the isobole and related quantitative methods for assessing drug synergism. Tallarida RJ J Pharmacol Exp Ther; 2012 Jul; 342(1):2-8. PubMed ID: 22511201 [TBL] [Abstract][Full Text] [Related]
35. Response envelope analysis for quantitative evaluation of drug combinations. Du D; Chang CH; Wang Y; Tong P; Chan WK; Chiu Y; Peng B; Tan L; Weinstein JN; Lorenzi PL Bioinformatics; 2019 Oct; 35(19):3761-3770. PubMed ID: 30851108 [TBL] [Abstract][Full Text] [Related]
36. Synergy evaluation of non-normalizable dose-response data: Generalization of combination index for the linear effect of drugs. Novotný B; Nagy M; Kurin E Pharm Stat; 2021 Nov; 20(6):982-989. PubMed ID: 33764621 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of drug combination effect using a Bliss independence dose-response surface model. Liu Q; Yin X; Languino LR; Altieri DC Stat Biopharm Res; 2018; 10(2):112-122. PubMed ID: 30881603 [TBL] [Abstract][Full Text] [Related]
38. In silico drug combination discovery for personalized cancer therapy. Jeon M; Kim S; Park S; Lee H; Kang J BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824 [TBL] [Abstract][Full Text] [Related]
39. Independent drug action and its statistical implications for development of combination therapies. Chen C; Liu F; Ren Y; Suttner L; Sun Z; Shentu Y; Schmidt EV Contemp Clin Trials; 2020 Nov; 98():106126. PubMed ID: 32853780 [TBL] [Abstract][Full Text] [Related]
40. Comparisons of Analysis Methods for Assessment of Pharmacodynamic Interactions Including Design Recommendations. Chen C; Wicha SG; Nordgren R; Simonsson USH AAPS J; 2018 Jun; 20(4):77. PubMed ID: 29931471 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]